A nurse manager commented: Our GLP-1 patients get their initial dose first week of therapy, not after a 2-week wait. No peer-reviewed publication documents this specific initiative (to our knowledge), but it aligns with published pilots ( [6] ) ( [7] )
The injection sites can include the abdomen, thigh, or upper arm
Standard dosing is evidence-based, while microdosing, using lower-than-prescribed doses, has gained attention despite limited evidence, with potential benefits offset by concerns about reduced efficacy, safety risks, and lack of clinical validation
These included gallbladder cancer (HR = 0.35), meningioma (HR = 0.37), pancreatic cancer (HR = 0.41), hepatocellular carcinoma (HR = 0.47), ovarian cancer (HR = 0.52), colorectal cancer (HR = 0.54), multiple myeloma (HR = 0.59), esophageal cancer (HR = 0.60), endometrial cancer (HR = 0.74), and kidney cancer (HR = 0.76)